RU2017125520A - Соединения, ингибирующие parg - Google Patents

Соединения, ингибирующие parg Download PDF

Info

Publication number
RU2017125520A
RU2017125520A RU2017125520A RU2017125520A RU2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A RU 2017125520 A RU2017125520 A RU 2017125520A
Authority
RU
Russia
Prior art keywords
methyl
sulfonamide
methylcyclopropyl
oxobenzimidazole
thiadiazol
Prior art date
Application number
RU2017125520A
Other languages
English (en)
Russian (ru)
Other versions
RU2017125520A3 (OSRAM
Inventor
Элисон Е. МАКГОНЕГЛ
Аллан М. ДЖОРДАН
Богдан ВАШКОВИЧ
Колин П. ХАТТОН
Ян Д. УОДДЕЛЛ
Джеймс Р. ХИТЧИН
Кейт М. СМИТ
Ниалл М. ГАМИЛЬТОН
Original Assignee
Кэнсер Рисерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсер Рисерч Текнолоджи Лимитед filed Critical Кэнсер Рисерч Текнолоджи Лимитед
Publication of RU2017125520A publication Critical patent/RU2017125520A/ru
Publication of RU2017125520A3 publication Critical patent/RU2017125520A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
RU2017125520A 2014-12-19 2015-12-17 Соединения, ингибирующие parg RU2017125520A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422771 2014-12-19
GB1422771.4 2014-12-19
PCT/GB2015/054064 WO2016097749A1 (en) 2014-12-19 2015-12-17 Parg inhibitory compounds

Publications (2)

Publication Number Publication Date
RU2017125520A true RU2017125520A (ru) 2019-01-21
RU2017125520A3 RU2017125520A3 (OSRAM) 2019-06-06

Family

ID=54937310

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125520A RU2017125520A (ru) 2014-12-19 2015-12-17 Соединения, ингибирующие parg

Country Status (16)

Country Link
US (4) US10508086B2 (OSRAM)
EP (2) EP3907224A1 (OSRAM)
JP (1) JP6673920B2 (OSRAM)
KR (1) KR102682782B1 (OSRAM)
CN (2) CN112979631B (OSRAM)
AU (1) AU2015365602B2 (OSRAM)
BR (1) BR112017012707B1 (OSRAM)
CA (1) CA2969298C (OSRAM)
ES (1) ES2886471T3 (OSRAM)
IL (1) IL252745B (OSRAM)
MA (1) MA41179A (OSRAM)
MX (1) MX380901B (OSRAM)
RU (1) RU2017125520A (OSRAM)
SG (1) SG11201704843QA (OSRAM)
WO (1) WO2016097749A1 (OSRAM)
ZA (1) ZA201704383B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
EP3947351A4 (en) 2019-03-29 2022-12-07 Board of Regents, The University of Texas System SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE
WO2021055744A1 (en) * 2019-09-20 2021-03-25 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
EP4401721A4 (en) 2021-10-17 2025-10-15 Univ Of South Alabama Foundation For Research And Commercialization CANCER TREATMENT
AR128499A1 (es) 2022-02-14 2024-05-15 Arase Therapeutics Inc Inhibidores de parg
CN116693519A (zh) 2022-03-04 2023-09-05 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
KR20240165402A (ko) 2022-03-23 2024-11-22 아이디어야 바이오사이언시스 인코포레이티드 Parg의 억제제로서의 피페라진 치환된 인다졸 화합물
CN114685283B (zh) * 2022-04-06 2024-02-27 南京艾康生物科技有限公司 一种1-(氟甲基)环丙胺盐酸盐的制备方法
IL316261A (en) * 2022-04-28 2024-12-01 Danatlas Pharmaceuticals Co Ltd Tricyclic and heterocyclic derivatives, preparations and uses thereof
WO2023205914A1 (en) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
KR20250012101A (ko) 2022-05-17 2025-01-23 858 테라퓨틱스, 인크. Parg의 억제제
CN117304183A (zh) * 2022-06-29 2023-12-29 杭州圣域生物医药科技有限公司 五元并六元含氮化合物、其中间体、制备方法和应用
EP4559912A1 (en) * 2022-07-19 2025-05-28 Evopoint Biosciences Co., Ltd. Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound
JP2025533274A (ja) * 2022-10-13 2025-10-03 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｙａｐ－ｔｅａｄ相互作用を阻害するための新規なヘテロ二環式化合物及びそれを含む薬学的組成物
WO2024120519A1 (zh) * 2022-12-09 2024-06-13 捷思英达控股有限公司 Tead抑制剂、其制备方法和在医学上的应用
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
CN121002021A (zh) * 2023-04-27 2025-11-21 北京丹擎医药科技有限公司 三环杂环衍生物及其组合物和应用
WO2024243304A2 (en) * 2023-05-23 2024-11-28 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds
CN119143747A (zh) * 2023-06-16 2024-12-17 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
TW202513045A (zh) * 2023-08-10 2025-04-01 美商雅瑞斯醫療公司 Parg抑制劑
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025073870A1 (en) 2023-10-03 2025-04-10 Forx Therapeutics Ag Parg inhibitory compound
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025098445A1 (zh) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Parg抑制剂及其制备方法和用途
WO2025108225A1 (zh) * 2023-11-20 2025-05-30 上海复星医药（集团）股份有限公司 作为parg抑制剂的含氮三环衍生物
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025229549A1 (en) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Novel heterocyclic compounds as inhibitors of parg

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (en) 1979-12-03 1983-11-29 Ikuo Ueda Quinazoline derivatives
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1065400A (en) 1998-11-12 2000-06-05 Bae Systems Electronics Limited Scanning of electromagnetic beams
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
US20070032496A1 (en) * 2005-07-26 2007-02-08 Hergenrother Paul J Compounds for the Treatment of Neurodegeneration and Stroke
EP1979314B1 (en) * 2006-01-24 2013-01-09 Eli Lilly & Company Indole sulfonamide modulators of progesterone receptors
CA2645583A1 (en) 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2211854A4 (en) 2007-10-19 2011-01-12 Bipar Sciences Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
RU2011105810A (ru) 2008-07-17 2012-08-27 Асахи Касеи Фарма Корпорейшн (Jp) Азотсодержащие бициклические гетероциклические соединения
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
MX2012008141A (es) 2010-01-13 2012-08-03 Glaxosmithkline Llc Compuestos y metodos.
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
PH12013501489A1 (en) 2010-12-17 2013-08-28 Hoffmann La Roche Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
US9938236B2 (en) 2012-12-27 2018-04-10 Drexel University Antiviral agents against HBV infection
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3947351A4 (en) 2019-03-29 2022-12-07 Board of Regents, The University of Texas System SMALL MOLECULAR PARG INHIBITORS AND METHODS OF USE
WO2021055744A1 (en) 2019-09-20 2021-03-25 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
WO2023057389A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag Parg inhibitory compounds
KR20240165402A (ko) 2022-03-23 2024-11-22 아이디어야 바이오사이언시스 인코포레이티드 Parg의 억제제로서의 피페라진 치환된 인다졸 화합물

Also Published As

Publication number Publication date
KR102682782B1 (ko) 2024-07-12
IL252745A0 (en) 2017-08-31
JP6673920B2 (ja) 2020-03-25
AU2015365602A1 (en) 2017-06-29
US12129236B2 (en) 2024-10-29
RU2017125520A3 (OSRAM) 2019-06-06
CN112979631B (zh) 2024-09-20
BR112017012707A2 (pt) 2018-01-02
MX380901B (es) 2025-03-12
EP3233845A1 (en) 2017-10-25
US20200165208A1 (en) 2020-05-28
US20180194738A1 (en) 2018-07-12
ZA201704383B (en) 2022-03-30
NZ732394A (en) 2024-01-26
ES2886471T3 (es) 2021-12-20
US10508086B2 (en) 2019-12-17
SG11201704843QA (en) 2017-07-28
CN107295799A (zh) 2017-10-24
EP3907224A1 (en) 2021-11-10
CN112979631A (zh) 2021-06-18
WO2016097749A1 (en) 2016-06-23
US20250223266A1 (en) 2025-07-10
EP3233845B1 (en) 2021-07-21
HK1245253A1 (zh) 2018-08-24
CA2969298A1 (en) 2016-06-23
JP2017538750A (ja) 2017-12-28
MA41179A (fr) 2017-10-24
KR20170095370A (ko) 2017-08-22
MX2017007976A (es) 2018-03-26
CN107295799B (zh) 2021-03-16
BR112017012707B1 (pt) 2023-10-24
US10995073B2 (en) 2021-05-04
IL252745B (en) 2020-03-31
CA2969298C (en) 2023-10-17
US20210380539A1 (en) 2021-12-09
AU2015365602B2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
RU2017125520A (ru) Соединения, ингибирующие parg
JP2017538750A5 (OSRAM)
RU2017124425A (ru) Производные 2,4-диоксо-хиназолин-6-сульфонамида в качестве ингибиторов parg
JP2010533158A5 (OSRAM)
RU2485114C2 (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
CA2559866A1 (en) Anaplastic lymphoma kinase modulators and methods of use
JP2007510689A5 (OSRAM)
JP2017508766A5 (OSRAM)
JP2018530591A5 (OSRAM)
JP2010513444A5 (OSRAM)
JP2011503166A5 (OSRAM)
JP2019504009A5 (OSRAM)
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
JP2007523905A5 (OSRAM)
JP2019519484A5 (OSRAM)
JP2016523911A5 (OSRAM)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2013516415A5 (OSRAM)
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2010540462A5 (OSRAM)
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
RU2019117556A (ru) Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
JP2010534673A (ja) 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物
JP2008501673A5 (OSRAM)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191121